Brief: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response
19/12/2025 13:30
Dec 19 (Reuters) - Galectin Therapeutics Inc GALT.O: GALECTIN THERAPEUTICS PROVIDES REGULATORY UPDATE FOLLOWING FDA WRITTEN RESPONSE AND ANNOUNCES AN ADDITIONAL $10 MILLION LINE OF CREDIT FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES THROUGH MARCH 2027 GALECTIN THERAPEUTICS INC - TO PURSUE FOLLOW-UP TYPE C MEETING Source text: ID:nGNXc7l6Zx Further company coverage: GALT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study